---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041689"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-09-08T11:05:42+00:00"
generated_at: "2026-09-08T11:10:08.681382+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Tonix Pharmaceuticals promotes Thomas Englese to Chief Commercial Officer

## Summary
- Thomas Englese appointed Chief Commercial Officer, effective Sept 8, 2026, after serving as EVP Commercial Operations since 2024.
- Englese oversees commercial organization for TONMYA (fibromyalgia) and migraine products Zembrace SymTouch and Tosymra.
- Previous roles include CCO at Tris Pharma and Aziyo, and SVP/GM at Mallinckrodt.
- CEO Seth Lederman cites Englese's role in TONMYA launch; focus on expanding access and sales.

## SEC filing metadata
- accession: 0001493152-26-041689
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-09-08T11:05:42+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000149315226041689/0001493152-26-041689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000149315226041689/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041689
- JSON: https://secwatch.observer/filing/0001493152-26-041689.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.